Artelis and Selexis Announce 31 g/L Yields in Multiple Perfusion Harvests

September 9, 2008

Artelis SA (Brussels, Belgium) and Selexis SA (Geneva, Switzerland) have announced  manufacturing yields of more than 31 grams per liter in a CHO-based monoclonal antibody production process, in multiple harvests from a perfusion-like process.

Artelis and Selexis Announce 31 g/L Yields in Multiple Perfusion Harvests
Artelis SA (Brussels, Belgium) and Selexis SA (Geneva, Switzerland) have announced  manufacturing yields of more than 31 grams per liter in a CHO-based monoclonal antibody production process, in multiple harvests from a perfusion-like process.

The high yields were achieved by applying a high-performance Selexis CHO production cell line and the iCELLis platform, a scalable, disposable, high-cell-density technology developed by scientists at Artelis.

The full program was concluded over about four months, starting with a high-performance cell line development at Selexis, followed by cell transfer and manufacturing at Artelis. The culture media used throughout the study was industry-standard cGMP grade and void of serum or any animal-derived components. Artelis and Selexis plan to expand the testing of the combined technologies by evaluating the iCELLis platform with Selexis-generated HEK293 cells lines.

iCELLis is a proprietary, single-use, technology developed by Artelis, designed to achieve and maintain high-cell densities on macrocarriers in a fixed-bed system. According to the company, these high-cell densities allow the compact iCELLis bioreactors to equal the productivity of much larger stirred-tank units.

Selexis release